-
-
I had a shock as well. totally didn't see it coming though i should have..
Ion Torrent seems to be in direct competition with their SOLID PI system.Comment
-
I don't think it is that shocking. This is similar to what Jonathan Rothberg (Ion Torrent founder & CEO) did when he founded 454. He developed the technology to the point it was ready to go into commercial production and sold out to a company with the resources make that happen.Comment
-
The 454 story is more convoluted. Rothberg had already left Curagen by 2007 to purse other interests. Roche was only a minority investor in the beginning. Then Curagen, having no idea how to run a sequencer company and figuring there was more promise in their drug pipeline (that eventually went nowhere), basically asked Roche what they'd like to pay for the remainder of 454, which turned out to be a paltry $152M.
All the investors who were into CRGN for 454 sold out immediately, and the stock plummeted.Comment
-
Competition would have brought down prices. Too bad that LIFE is buying everything now. They and Illumina can basically price gouge.Comment
-
i posted some of my thoughts about the future of Ion Torrent, with an emphasis on clinical applications here:
http://jermdemo.blogspot.com/2010/08...on-of-ion.htmlComment
-
Will the current NGS products soon be replaced or are the new instruments just additive to the market?Comment
-
The projected price of the Ion Torrent used to be 50K- now it is "less than 100K" in the new press releases...wait till we see the reagent costs!Comment
-
The HiSeq is backordered for so long maybe people should just cancel their order and wait for this?Comment
-
IonTorrent compares very poorly to HiSeq for really high throughput sequencing -- remember the claim is that each run will generate 150Mb (1M reads x ~150nt) of data for $500; HiSeq will generate on the order of (from memory; feel free to dispute with hard data!) 100Gb for $10K -- if you equalize those then Ion Torrent for $10K will generate only 3Gb (20*150Mb) -- about 1/30th the data for the same consumable cost.
Of course, I've left out equipment amortization from that. If you really use the sequencer flat out, HiSeq should still win (even if Ion comes in at $50K) -- and Ion Torrent will require hourly attention to care-and-feed (the videos I've seen do NOT look automation friendly -- someone snapping a new cartridge in each time), meaning higher labor costs.
On the other hand, to rapidly turn around small batches (such as amplicons), Ion Torrent will probably win -- it will do that run in an hour vs. around a week for HiSeq. Now, the appropriate comparator is really 454 and even with 454 Jr the Ion Torrent looks good -- a lot of data cheaply, if really long reads aren't critical for you.
Ion Torrent claimed that next year they would have a chip with about 4X the density. If priced the same (unlikely, but possible) then it's stlll not the price-performance of HiSeq when generating huge amounts of data from a given sample or set of samples with little time pressure.Comment
-
No the specs are
Thus the output is actually higher than the GAIIXLife Tech plans to scale the system up from a current throughput of 2 gigabases per four-hour run to 4 gigabases per four-hour run in the next year by increasing the number of features on the chip from a current level of 7.3 million features to 12.9 million features.
http://www.genomeweb.com/node/947587Comment
-
I hate to disagree, but I believe that quote is from a stock analyst named Jon Groberg : "In a research note analyzing the acquisition, Jon Groberg of Macquarie Research said that even though Ion Torrent has no "meaningful revenues," Macquarie approves of the acquisition "as we think the technology has the potential to be more disruptive than any other technology near nearing the market."
"In addition, Groberg said that Life Tech plans to scale the system up from a current throughput of 2 gigabases per four-hour run to 4 gigabases per four-hour run in the next year by increasing the number of features on the chip from a current level of 7.3 million features to 12.9 million features."
The previous estimates of ~1,000,000 reads with the 316 chip matches what our friendly ion torrent rep told us two weeks ago. The chip itself has far more than 1,000,000 features, but they are currently only getting useful data from about 1,000,000 of those features per run. I assume the stock analyst just read the spec sheet and never talked with anyone who has actual experience with the instrument. But perhaps I'm jumping to the wrong conclusions since I'm not all that fond of stock analysts.
Originally posted by NextGenSeq View PostComment
-
let's not be myopic here - this debate is beginning to sound like someone in 1985 comparing an Apple Laserwriter to a full-blown printing press. Yes the printing press has more throughput but that isn't the point. The PGM (or a successor) will find its way to a clinical setting within our lifetime.Comment
-
Even at 150MB per hour run that approaches the GAIIX throughput. Admittedly it's more expensive per bp. Also, supposedly the error rate is high and homopolymer stretches are a problem as with the 454.Comment
Tweet
-
Amplicon sequencing is a targeted approach that allows researchers to investigate specific regions of the genome. This technique is routinely used in applications such as variant identification, clinical research, and infectious disease surveillance. The amplicon sequencing process begins by designing primers that flank the regions of interest. The DNA sequences are then amplified through PCR (typically multiplex PCR) to produce amplicons complementary to the targets. RNA targets...03-21-2023, 01:49 PM -
Targeted sequencing is an effective way to sequence and analyze specific genomic regions of interest. This method enables researchers to focus their efforts on their desired targets, as opposed to other methods like whole genome sequencing that involve the sequencing of total DNA. Utilizing targeted sequencing is an attractive option for many researchers because it is often faster, more cost-effective, and only generates applicable data. While there are many approaches...03-10-2023, 05:31 AM
Comment